Compare LPA & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LPA | ATYR |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | N/A | 58 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 73.7M |
| IPO Year | 2023 | N/A |
| Metric | LPA | ATYR |
|---|---|---|
| Price | $3.27 | $0.80 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.67 |
| AVG Volume (30 Days) | 19.6K | ★ 939.9K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.04 | $0.64 |
| 52 Week High | $9.41 | $7.29 |
| Indicator | LPA | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 65.13 | 44.45 |
| Support Level | $2.51 | $0.68 |
| Resistance Level | $3.66 | $0.85 |
| Average True Range (ATR) | 0.24 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 65.04 | 48.87 |
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).